387827-25-0

Basic information

• Product Name: N-(3-(piperidin-4-yl)phenyl)acetamide hydrochloride
• Synonyms: Acetamide, N-[3-(4-piperidinyl)phenyl]-
• CAS NO: 387827-25-0
• Molecular Formula: C₁₃H₁₈N₂O
• Molecular Weight: 254.75576
• EINECS: -0
• Mol File: 387827-25-0.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(3-(piperidin-4-yl)phenyl)acetamide hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-(piperidin-4-yl)phenyl)acetamide hydrochloride(387827-25-0)
• EPA Substance Registry System: N-(3-(piperidin-4-yl)phenyl)acetamide hydrochloride(387827-25-0)

Safety Data

• Hazardous Substances Data: 387827-25-0(Hazardous Substances Data)

Upstream product

• 159503-90-9 C₁₀H₁₇NO₃ 
• 387827-20-5 tert-butyl 4-[3-(acetylamino)-phenyl]-1,2,3,6-tetrahydro-1-pyridinecarboxylate 
• 387827-18-1 tert-butyl 4-[3-(amino)phenyl]-1,2,3,6-tetrahydro-1-pyridinecarboxylate 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 387827-24-9 tert-butyl 4-[3-(acetylamino)-phenyl]-1-piperidinecarboxylate 

Downstream Products

• 875004-84-5 N-(3-{1-[2-(1,3-dioxoisoindolin-2-yl)ethyl]piperidin-4-yl}phenyl)acetamide 
• 1373341-11-7 4-(5-chlorothiophen-2-yl)-2-[3-[4-[3-(acetylamino)phenyl]piperidine-1-yl]propyl]phthalazin-1(2H)-one 
• 1372156-05-2 C₂₉H₃₁N₅O₂ 
• 1372156-06-3 C₂₉H₃₁N₅O₂ 
• 1372156-08-5 C₂₉H₃₀ClN₅O₂ 
• 1372156-09-6 C₂₉H₃₀ClN₅O₂ 
• 1372156-10-9 C₂₉H₂₉Cl₂N₅O₂ 
• 1372156-11-0 C₂₉H₃₁N₅O₂ 
• 1372156-13-2 C₂₉H₃₀ClN₅O₂ 
• 1372156-12-1 C₂₉H₃₁N₅O₃ 
• 1373341-12-8 C₂₈H₃₀N₄O₃ 
• 1373341-09-3 C₂₈H₃₀N₄O₂S 
• 1373341-10-6 C₂₉H₃₂N₄O₂S 
• 1373341-14-0 C₂₉H₃₃N₅O₂ 

Relevant articles and documents

Syntheses of precursors and reference compounds of the melanin- concentrating hormone receptor 1 (MCHR1) Tracers [11C]SNAP-7941 and [18F]FE@SNAP for positron emission tomography

The MCH receptor has been revealed as a target of great interest in positron emission tomography imaging. The receptor's eponymous substrate melanin-concentrating hormone (MCH) is a cyclic peptide hormone, which is located predominantly in the hypothalamus with a major influence on energy and weight regulation as well as water balance and memory. Therefore, it is thought to play an important role in the pathophysiology of adiposity, which is nowadays a big issue worldwide. Based on the selective and high-affinity MCH receptor 1 antagonist SNAP-7941, a series of novel SNAP derivatives has been developed to provide different precursors and reference compounds for the radiosyntheses of the novel PET radiotracers [11C]SNAP-7941 and [18F] FE@SNAP. Positron emission tomography promotes a better understanding of physiologic parameters on a molecular level, thus giving a deeper insight into MCHR1 related processes as adiposity.

DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof

This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention further provides a method of treating a subject suffering from urinary incontinence which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's urinary incontinence.

SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.